BioLife Solutions (NASDAQ:BLFS) EVP Sells $10,363.95 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 405 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $25.59, for a total transaction of $10,363.95. Following the completion of the sale, the executive vice president directly owned 349,350 shares in the company, valued at $8,939,866.50. This trade represents a 0.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

BioLife Solutions Price Performance

NASDAQ:BLFS traded down $0.46 during trading hours on Thursday, reaching $24.95. 268,601 shares of the company were exchanged, compared to its average volume of 364,400. The stock has a 50 day simple moving average of $25.51 and a 200 day simple moving average of $24.81. BioLife Solutions, Inc. has a 52-week low of $19.10 and a 52-week high of $29.62. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -356.38 and a beta of 1.93.

Institutional Trading of BioLife Solutions

A number of institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada raised its stake in BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock worth $15,948,000 after buying an additional 617,320 shares during the period. Qube Research & Technologies Ltd grew its stake in shares of BioLife Solutions by 2,399.5% in the second quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock valued at $5,352,000 after buying an additional 238,533 shares in the last quarter. Summit Creek Advisors LLC bought a new stake in shares of BioLife Solutions in the 3rd quarter valued at about $4,905,000. Mutual of America Capital Management LLC lifted its position in shares of BioLife Solutions by 22.2% in the second quarter. Mutual of America Capital Management LLC now owns 638,373 shares of the medical equipment provider’s stock valued at $13,751,000 after buying an additional 115,963 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in BioLife Solutions by 11.3% during the second quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider’s stock worth $23,271,000 after purchasing an additional 109,959 shares during the period. 93.24% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on BLFS. UBS Group reissued a “buy” rating on shares of BioLife Solutions in a report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a research report on Monday, December 29th. Northland Securities set a $34.00 price target on shares of BioLife Solutions in a research note on Monday. Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. Finally, Zacks Research downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $32.00.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.